Trillium offers a rewarding, diverse and inclusive workplace, with a team dedicated to improving the lives of cancer patients. Innovative breakthroughs by Fluorinov Pharma, which was acquired by Trillium in 2016, enable unique, proprietary fluorine chemical synthesis that has the potential to transform promising compounds into superior drugs.Combining our expertise in synthetic chemistry and immuno-oncology to create tomorrow’s breakthroughs.The phagocytic activity of macrophages is regulated by both activating (“eat”) and inhibitory (“do not eat”) signals. The office will house a portion of Trillium’s clinical development team and is expected to provide access to an expanded talent pool of drug development professionals as Trillium … CAMBRIDGE, MA, July 6, 2020 – Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) (the “Corporation”), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced the voting results from its Annual and Special Meeting of Please note that Trillium is not seeking assistance or accepting unsolicited resumes from search firms for listed employment opportunities. CAMBRIDGE, MA, April 8, 2020 – Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided an update on the Company’s clinical trial activities and business operations in light of the COVID-19 pandemic.
Our lead CD47 blocker, TTI-621, is a potent, dual function molecule that is designed to inhibit CD47 on the tumor cell and simultaneously deliver an activating signal to the immune system, whereas most competitor CD47 blockers require a second drug for full activation.
Local delivery of TTI-621 was well tolerated, with no treatment-related > Grade 3 adverse events or dose-limiting toxicity observed in 27 mycosis fungoides patients.
In addition, Trillium’s SIRPαFc decoy receptors do not bind to normal human red blood cells. These responses occurred rapidly within the 2-week induction period. CAMBRIDGE, Mass., July 06, 2020 -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) (the “Corporation”), a clinical stage immuno-oncology company developing innovative therapies. Trillium Therapeutics USA is located at 100 Cambridgepark Dr, Cambridge, MA 02140. Trillium also announced today the opening of an office in Cambridge, Massachusetts.
Trillium Therapeutics (1) Demoulas Super Markets, Inc (1) Norwood Animal Hospital (1) Love's Travel Stops & Country Stores (1) Experience Level. Our commitment to fighting cancer begins in our laboratories and board rooms but extends to our community at large with participation in events such as Rexall’s OneWalk to Conquer Cancer to raise funds for Princess Margaret Cancer Centre. Mobilizing both the innate and the adaptive branches of the immune system to disarm and defeat cancerWe have a strong focus on CD47, a molecule that tumors frequently use to evade the immune system. Life at Trillium . CD47 serves as a critical “do not eat” signal inhibiting phagocytosis by binding to signal regulatory protein alpha (SIRPα) on the surface of macrophages. In addition to their direct anti-tumor activity, cells of the innate immune system play a key role in recruiting and activating the adaptive immune system, which provides specificity and memory. CAMBRIDGE, Mass., May 29, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. ("Trillium" or the "Company") (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today data from an ongoing phase 1 dose escalation study of TTI-622 in patients with advanced relapsed or refractory lymphoma. 100 Cambridgepark Drive, Suite 510 Cambridge, MA 02140 USA Tel: +1 857.412.7029. At Trillium, employees work in an enriching environment that promotes team building, mutual respect and fairness. Trillium Therapeutics Inc. (NASDAQ/TSX:TRIL) is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The data are … Thrombocytopenia was the most frequent grade 3 or higher treatment-emergent adverse event, occurring in 18% of patients. We are also developing novel new chemical entities directed against other immuno-oncology targets such as STING.Blocking CD47 with SIRPαFc decoy receptors may activate both the innate and the adaptive immune systems.CD47 delivers a “do not eat” signal to macrophages through its interaction with SIRPα, allowing cancer cells to escape the immune system.Developing two unique SIRPαFc decoy receptors to prevent cancer cells from escaping the immune system and triggering their destruction.We believe that our approach has advantages over our competitors. Displayed here are Job Ads that match your query. CAMBRIDGE, MA, March 10, 2020 - Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results, including an update on its transformation program, for the year ended December 31, … Trillium is also developing TTI-622, a second anti-CD47 product candidate with potential advantages for combination therapy (NCT03530683).
TTI-622 is Trillium’s second SIRPαFc fusion protein. This effect is seen across a range of both blood and solid cancers.